BACKGROUND: The authors conducted a retrospective study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for hematological malignancy. PATIENTS AND METHODS: The authors examined 108 patients (63 male, 45 female) 5-29 years old, (median 15 years). All patients were in long-term remission of their malignancy. The cardioprotection was given to 68 patients (39 male, 29 female), and standard treatment was used in 40 patients (24 male, 16 female). Dexrazoxane (cardioxane, Chiron Company, The Netherlands) was given in 20:1 ratio to anthracycline. The follow-up time was 2-20 years (mean 7 years). The control group consisted of 41 volunteers (22 males, 19 females) 4-31 years old (median 18 years). The cardiotoxicity has been defined as the presence of heart failure or the decline of shortening fraction below 30% or ejection fraction (EF) below 55%. The end-systolic wall stress (ESS), myocardial performance index (MPI; Tei index), and parameters of left ventricular diastolic filling were also assessed. RESULTS: The anthracycline cardiomyopathy with the presence of heart failure was diagnosed in only one patient treated with a standard regimen. The pathological decline of fractional shortening was present in three (5%) and six (15%) patients with and without cardioprotection given, respectively. Similarly, none of the patients with cardioprotection revealed a pathological value of EF, while four (10%) patients without cardioprotection showed an EF decrease. Finally, ESS and isovolumic relaxation time were pathologically increased in the group without cardioprotection in comparison to the controls and to the group with cardioprotection. However, the MPI was significantly increased in both groups of patients. CONCLUSIONS: Dexrazoxane reduces the risk of late clinical and subclinical cardiotoxicity and does not affect the response rates to chemotherapy and overall survival during the median follow-up period of 7 years (follow-up period 2-20 years).

Department of Cardiopulmonary Testing University Hospital Brno Jihlavska 20 Brno 62500 Czech Republic

Zobrazit více v PubMed

Eur J Heart Fail. 2002 Jun;4(3):235-42 PubMed

Ann Intern Med. 1979 Nov;91(5):710-7 PubMed

Pediatrics. 1992 May;89(5 Pt 1):942-9 PubMed

Cancer Treat Rev. 1991 Mar;18(1):1-19 PubMed

J Pediatr Hematol Oncol. 1996 Feb;18(1):72-5 PubMed

JAMA. 1991 Sep 25;266(12 ):1672-7 PubMed

J Clin Oncol. 2002 Mar 15;20(6):1677-82 PubMed

Am J Med. 1977 Feb;62(2):200-8 PubMed

Am J Cardiol. 2001 May 1;87(9):1120-2, A9 PubMed

Drugs. 1998 Sep;56(3):385-403 PubMed

Cancer Treat Rev. 1993 Jan;19(1):57-77 PubMed

Clin Cardiol. 2001 Oct;24(10):663-9 PubMed

J Cardiol. 1995 Dec;26(6):357-66 PubMed

N Engl J Med. 1991 Mar 21;324(12):808-15 PubMed

Cancer Treat Rep. 1978 Jun;62(6):873-9 PubMed

J Clin Oncol. 1996 Feb;14(2):362-72 PubMed

Curr Med Chem. 2001 Nov;8(13):1649-60 PubMed

Br Heart J. 1995 Apr;73(4):340-50 PubMed

Drugs. 2002;62(14):2089-126 PubMed

Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):131-9 PubMed

J Clin Oncol. 2002 Jun 15;20(12):2895-903 PubMed

Ann Intern Med. 1996 Jul 1;125(1):47-58 PubMed

N Engl J Med. 1995 Jun 29;332(26):1738-43 PubMed

Med Pediatr Oncol. 1995 Jun;24(6):352-61 PubMed

Pediatr Hematol Oncol. 1997 May-Jun;14(3):213-22 PubMed

Curr Med Chem. 1998 Feb;5(1):1-28 PubMed

Crit Rev Oncol Hematol. 1998 Jan;27(1):53-68 PubMed

Br Heart J. 1993 Aug;70(2):185-8 PubMed

Med Pediatr Oncol. 1998 Dec;31(6):512-5 PubMed

Pediatr Cardiol. 1999 Jul-Aug;20(4):252-63 PubMed

Semin Oncol. 1998 Oct;25(5):525-37 PubMed

Cancer Prev Control. 1999 Apr;3(2):145-59 PubMed

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection